Cargando…
Evaluation of a Produce Prescription Program for Patients With Diabetes: A Longitudinal Analysis of Glycemic Control
OBJECTIVE: Produce prescriptions have shown promise in improving diabetes care, although most studies have used small samples or lacked controls. Our objective was to evaluate the impacts of a produce prescription program on glycemic control for patients with diabetes. RESEARCH DESIGN AND METHODS: P...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Diabetes Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234740/ https://www.ncbi.nlm.nih.gov/pubmed/36812470 http://dx.doi.org/10.2337/dc22-1645 |
_version_ | 1785052562952552448 |
---|---|
author | Hager, Kurt Shi, Peilin Li, Zhongyu Chui, Kenneth Berkowitz, Seth A. Mozaffarian, Dariush Chhabra, Jyoti Wilken, Joel Vergara, Cunegundo Becker, Erica Small, Sara Ling, Brent Cash, Sean B. Folta, Sara C. Zhang, Fang Fang |
author_facet | Hager, Kurt Shi, Peilin Li, Zhongyu Chui, Kenneth Berkowitz, Seth A. Mozaffarian, Dariush Chhabra, Jyoti Wilken, Joel Vergara, Cunegundo Becker, Erica Small, Sara Ling, Brent Cash, Sean B. Folta, Sara C. Zhang, Fang Fang |
author_sort | Hager, Kurt |
collection | PubMed |
description | OBJECTIVE: Produce prescriptions have shown promise in improving diabetes care, although most studies have used small samples or lacked controls. Our objective was to evaluate the impacts of a produce prescription program on glycemic control for patients with diabetes. RESEARCH DESIGN AND METHODS: Participants included a nonrandom enrollment of 252 patients with diabetes who received a produce prescription and 534 similar control participants from two clinics in Hartford, Connecticut. The start of the COVID-19 pandemic in March 2020 coincided with program implementation. Produce prescription enrollees received vouchers ($60 per month) for 6 months to purchase produce at grocery retail. Controls received usual care. The primary outcome was change in glycated hemoglobin (HbA(1c)) between treatment and control at 6 months. Secondary outcomes included 6-month changes in systolic (SBP) and diastolic blood pressure (DBP), BMI, hospitalizations, and emergency department admissions. Longitudinal generalized estimating equation models, weighted with propensity score overlap weights, assessed changes in outcomes over time. RESULTS: At 6 months, there was no significant difference in change in HbA(1c) between treatment and control groups, with a difference of 0.13 percentage points (95% CI −0.05, 0.32). No significant difference was observed for change in SBP (3.85 mmHg; −0.12, 7.82), DBP (−0.82 mmHg; −2.42, 0.79), or BMI (−0.22 kg/m(2); −1.83, 1.38). Incidence rate ratios for hospitalizations and emergency department visits were 0.54 (0.14, 1.95) and 0.53 (0.06, 4.72), respectively. CONCLUSIONS: A 6-month produce prescription program for patients with diabetes, implemented during the onset of the COVID-19 pandemic, was not associated with improved glycemic control. |
format | Online Article Text |
id | pubmed-10234740 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Diabetes Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-102347402023-06-02 Evaluation of a Produce Prescription Program for Patients With Diabetes: A Longitudinal Analysis of Glycemic Control Hager, Kurt Shi, Peilin Li, Zhongyu Chui, Kenneth Berkowitz, Seth A. Mozaffarian, Dariush Chhabra, Jyoti Wilken, Joel Vergara, Cunegundo Becker, Erica Small, Sara Ling, Brent Cash, Sean B. Folta, Sara C. Zhang, Fang Fang Diabetes Care Original Article OBJECTIVE: Produce prescriptions have shown promise in improving diabetes care, although most studies have used small samples or lacked controls. Our objective was to evaluate the impacts of a produce prescription program on glycemic control for patients with diabetes. RESEARCH DESIGN AND METHODS: Participants included a nonrandom enrollment of 252 patients with diabetes who received a produce prescription and 534 similar control participants from two clinics in Hartford, Connecticut. The start of the COVID-19 pandemic in March 2020 coincided with program implementation. Produce prescription enrollees received vouchers ($60 per month) for 6 months to purchase produce at grocery retail. Controls received usual care. The primary outcome was change in glycated hemoglobin (HbA(1c)) between treatment and control at 6 months. Secondary outcomes included 6-month changes in systolic (SBP) and diastolic blood pressure (DBP), BMI, hospitalizations, and emergency department admissions. Longitudinal generalized estimating equation models, weighted with propensity score overlap weights, assessed changes in outcomes over time. RESULTS: At 6 months, there was no significant difference in change in HbA(1c) between treatment and control groups, with a difference of 0.13 percentage points (95% CI −0.05, 0.32). No significant difference was observed for change in SBP (3.85 mmHg; −0.12, 7.82), DBP (−0.82 mmHg; −2.42, 0.79), or BMI (−0.22 kg/m(2); −1.83, 1.38). Incidence rate ratios for hospitalizations and emergency department visits were 0.54 (0.14, 1.95) and 0.53 (0.06, 4.72), respectively. CONCLUSIONS: A 6-month produce prescription program for patients with diabetes, implemented during the onset of the COVID-19 pandemic, was not associated with improved glycemic control. American Diabetes Association 2023-06 2023-02-22 /pmc/articles/PMC10234740/ /pubmed/36812470 http://dx.doi.org/10.2337/dc22-1645 Text en © 2023 by the American Diabetes Association https://www.diabetesjournals.org/journals/pages/licenseReaders may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license. |
spellingShingle | Original Article Hager, Kurt Shi, Peilin Li, Zhongyu Chui, Kenneth Berkowitz, Seth A. Mozaffarian, Dariush Chhabra, Jyoti Wilken, Joel Vergara, Cunegundo Becker, Erica Small, Sara Ling, Brent Cash, Sean B. Folta, Sara C. Zhang, Fang Fang Evaluation of a Produce Prescription Program for Patients With Diabetes: A Longitudinal Analysis of Glycemic Control |
title | Evaluation of a Produce Prescription Program for Patients With Diabetes: A Longitudinal Analysis of Glycemic Control |
title_full | Evaluation of a Produce Prescription Program for Patients With Diabetes: A Longitudinal Analysis of Glycemic Control |
title_fullStr | Evaluation of a Produce Prescription Program for Patients With Diabetes: A Longitudinal Analysis of Glycemic Control |
title_full_unstemmed | Evaluation of a Produce Prescription Program for Patients With Diabetes: A Longitudinal Analysis of Glycemic Control |
title_short | Evaluation of a Produce Prescription Program for Patients With Diabetes: A Longitudinal Analysis of Glycemic Control |
title_sort | evaluation of a produce prescription program for patients with diabetes: a longitudinal analysis of glycemic control |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10234740/ https://www.ncbi.nlm.nih.gov/pubmed/36812470 http://dx.doi.org/10.2337/dc22-1645 |
work_keys_str_mv | AT hagerkurt evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT shipeilin evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT lizhongyu evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT chuikenneth evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT berkowitzsetha evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT mozaffariandariush evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT chhabrajyoti evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT wilkenjoel evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT vergaracunegundo evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT beckererica evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT smallsara evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT lingbrent evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT cashseanb evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT foltasarac evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol AT zhangfangfang evaluationofaproduceprescriptionprogramforpatientswithdiabetesalongitudinalanalysisofglycemiccontrol |